Hayward-based Solta Medical has been acquired by Valeant Pharmaceuticals, in a deal worth approximately $250M. Valeant said it will pay $2.92 per share in cash for Solta, which develops aesthetic medicine medical devices, including RF devices for skin tightening. Solta hd revenues of approximately $145M in 2012. Solta was advised by Piper Jaffray & Co. and Fenwick & West LLP. Valeant was advised by Skadden, Arps, Slate, Meagher & Flom LLP.